198 related articles for article (PubMed ID: 29380731)
41. [Accidental shortening time of high dose methotrexate infusion: case report and literature review].
Charfi R; Salouage I; Trabelsi S; Zarrouk M; Gaïes E; Jebabli N; Meddeb B; Lakhal M; Klouz A
Ann Biol Clin (Paris); 2013; 71(2):219-22. PubMed ID: 23587592
[TBL] [Abstract][Full Text] [Related]
42. Treatment of two cases on the same day of intrathecal methotrexate overdose using cerebrospinal fluid exchange and intrathecal instillation of carboxypeptidase-G2.
Wormdal OM; Flægstad T; Stokland T
Pediatr Hematol Oncol; 2018; 35(5-6):350-354. PubMed ID: 30672361
[TBL] [Abstract][Full Text] [Related]
43. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.
Yang CH; Yang LJ; Jaing TH; Chan HL
Int J Dermatol; 2000 Aug; 39(8):621-3. PubMed ID: 10971734
[TBL] [Abstract][Full Text] [Related]
44. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
45. Nephrotoxicity due to intermediate-dose methotrexate without rescue in an obese adolescent with acute lymphoblastic leukemia.
Sauer M; Rydholm N; Piatkowski J; Lewis V; Steiner M
Pediatr Hematol Oncol; 2002 Mar; 19(2):135-40. PubMed ID: 11881788
[TBL] [Abstract][Full Text] [Related]
46. Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
Widemann BC
Pediatr Blood Cancer; 2015 Sep; 62(9):1512-3. PubMed ID: 25940351
[No Abstract] [Full Text] [Related]
47. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
48. Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available.
Rosales A; Madrid A; Muñoz M; Dapena JL; Ariceta G
Front Pediatr; 2021; 9():635152. PubMed ID: 34490152
[No Abstract] [Full Text] [Related]
49. [Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].
Tatsumoto C; Kawakami K; Nagayama J; Kawano H
Rinsho Ketsueki; 2004 Oct; 45(10):1100-4. PubMed ID: 15553044
[TBL] [Abstract][Full Text] [Related]
50. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
[TBL] [Abstract][Full Text] [Related]
51. Glucarpidase for methotrexate nephrotoxicity: another string to our bow.
Koratala A; Ruchi R
Intern Med J; 2017 Nov; 47(11):1327. PubMed ID: 29105263
[No Abstract] [Full Text] [Related]
52. Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Meyers PA
Pediatr Blood Cancer; 2016 Feb; 63(2):364. PubMed ID: 26488216
[No Abstract] [Full Text] [Related]
53. Reduced-dose carboxypeptidase-G2 successfully lowers elevated methotrexate levels in an adult with acute methotrexate-induced renal failure.
Trifilio S; Ma S; Petrich A
Clin Adv Hematol Oncol; 2013 May; 11(5):322-3. PubMed ID: 23880719
[No Abstract] [Full Text] [Related]
54. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Scott JR; Crews KR
Pediatr Blood Cancer; 2016 Feb; 63(2):365. PubMed ID: 26488798
[No Abstract] [Full Text] [Related]
55. Pharmacokinetics and Pharmacodynamics of Glucarpidase Rescue Treatment After High-dose Methotrexate Therapy Based on Modeling and Simulation.
Kimura T; Fukaya Y; Hamada Y; Yoshimura K; Kawamoto H
Anticancer Res; 2023 May; 43(5):1919-1924. PubMed ID: 37097666
[TBL] [Abstract][Full Text] [Related]
56. [Digestive disease in the immunocompromised patient with acute lymphoblastic leukemia. Experience of the IVth Pediatric Clinic--Oncology Department of the Iaşi Sfânta Maria Children's Hospital].
Moisă SM; Rusu A; Dumitraş S; Burlea M; Miron I
Rev Med Chir Soc Med Nat Iasi; 2008; 112(2):356-65. PubMed ID: 19295004
[TBL] [Abstract][Full Text] [Related]
57. Production of "biobetter" variants of glucarpidase with enhanced enzyme activity.
Al-Qahtani AD; Bashraheel SS; Rashidi FB; O'Connor CD; Romero AR; Domling A; Goda SK
Biomed Pharmacother; 2019 Apr; 112():108725. PubMed ID: 30970523
[TBL] [Abstract][Full Text] [Related]
58. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
59. Hispanic ethnicity as a risk factor for requiring glucarpidase rescue in pediatric patients receiving high-dose methotrexate.
Schafer ES; Bernhardt MB; Reichert KE; Haworth TE; Shah MD
Am J Hematol; 2018 Feb; 93(2):E40-E42. PubMed ID: 29119597
[No Abstract] [Full Text] [Related]
60. Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury.
Sakran R; Milo G; Jabareen A; Artul T; Haim N; Litvak M; Ringelstein-Harlev S; Horowitz N; Efrati E; Assady S; Kurnik D
J Oncol Pharm Pract; 2022 Mar; 28(2):508-515. PubMed ID: 34668443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
